Antonio
Muñoz Callejas
Publikationen (26) Publikationen von Antonio Muñoz Callejas
2024
-
PSGL-1, ADAM8, and selectins as potential biomarkers in the diagnostic process of systemic lupus erythematosus and systemic sclerosis: an observational study
Frontiers in Immunology, Vol. 15
-
Regulation of monocyte apoptosis and DNA extrusion in monocyte extracellular traps by PSGL-1: Relevance in systemic lupus erythematosus
Translational Research, Vol. 274, pp. 10-20
2023
-
Analysis of the interstitial lung disease pathogenesis in PSGL-1 KO and P-Selectin KOmice
44 Congreso de las Sociedad Española de Inmunología
-
Diagnostic predictive value of soluble PSGL-1 and its ligands in patients with Systemicsclerosis (SSc)
44 Congreso de las Sociedad Española de Inmunología
-
Interstitial Lung Disease Associated with Systemic Sclerosis; New Molecules, New Routes of Administration
JOURNAL OF PHARMACEUTICAL ANALYSIS, Vol. 12
-
Low P-Selectin Glycoprotein Ligand-1 Expression in Neutrophils Associates with Disease Activity and Deregulated NET Formation in Systemic Lupus Erythematosus
International Journal of Molecular Sciences, Vol. 24, Núm. 7, pp. 6144
-
P-selectin/PSGL-1 axis regulation of autophagy in monocytes from healthy donors andlupus patients
44 Congreso de las Sociedad Española de Inmunología
-
PSGL-1/P-selectin interaction reduces the amount of DNA released in monocytesextracelular traps: lack of regulation in SLE patients
44 Congreso de las Sociedad Española de Inmunología
2022
-
Characterization of interstitial lung disease present in PSelectin KO mice (Lupus-likesyndrome) and PSGL-1 KO mice (Scleroderma-like syndrome)
43 Congreso de las Sociedad Española de Inmunología
-
PSGL-1/P-selectin axis in the homeostasis of monocytes from healthy donors, lupus andscleroderma patients
43 Congreso de las Sociedad Española de Inmunología
-
Targeted nanotherapy with everolimus reduces inflammation and fibrosis in scleroderma-related interstitial lung disease developed by PSGL-1 deficient mice
British Journal of Pharmacology, Vol. 179, Núm. 18, pp. 4534-4548
2021
-
Efecto del everolimus en el tratamiento de la neumonía intersticial asociada a esclerosissistémica en ratones PSGL-1 KO
42 Congreso de la Sociedad Española de Inmunología
-
IGF-1 facilitates extinction of conditioned fear
eLife, Vol. 10
-
Intratracheal Instillation of Everolimus Included In HA-decorated Liposomes, as SSc-ILDTreatment in mice
Nanotechnology and Chronic Diseases
-
Lung targeted delivery of Everolimus as a new treatment of Scleroderma-relatedinterstitial lung disease (SSC-ILD) developed by PSGL-1 KO mice
Annual European Congress of Rheumatology EULAR 2021
-
PSGL-1/P-Selectin interaction controls generation of NETs in human neutrophils
42 Congreso de la Sociedad Española de Inmunología
-
Signaling of PSGL-1 in human neutrophils might control NET generation and apoptosisand might be altered in SLE patients
Annual European Congress of Rheumatology EULAR 2021
-
miR-320c Regulates SERPINA1 Expression and Is Induced in Patients With Pulmonary Disease
Archivos de Bronconeumología (English Edition), Vol. 57, Núm. 7, pp. 457-463
2020
-
Estudio preliminar del tratamiento con Everolimus de la neumonía intersticial asociada aesclerosis sistémica en ratones PSGL-1 KO
XLVI Congreso Nacional de la SER
-
Relevance of PSGL-1 Expression in B Cell Development and Activation
Frontiers in Immunology, Vol. 11